Clinical Trials Browser

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05121038 2024-12-17

CENDIFOX

Phase 1/2 Active not recruiting

50 enrolled

Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT05546411 2024-12-17

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Phase 2 Terminated

8 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01905150 2024-12-11

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

Phase 2 Completed

34 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02919787 2024-11-20

Nordic Pancreatic Cancer Trial (NorPACT) - 1

Phase 2/3 Active not recruiting

140 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04927780 2024-08-28

PREOPANC-3

Phase 3 Recruiting

378 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06475326 2024-08-09

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

Phase 2 Recruiting

87 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04672005 2024-05-16

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

Phase 2 Active not recruiting

30 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04447092 2024-04-19

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Phase 2 Active not recruiting

77 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06361316 2024-04-11

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Phase NA Recruiting

53 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05048524 2024-03-27

Peri-operative SLOG for Localized Pancreatic Cancer

Phase 2 Unknown

64 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06259058 2024-03-15

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Phase 1/2 Not yet recruiting

96 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06217042 2024-01-22

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Phase 3 Not yet recruiting

524 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06210360 2024-01-18

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Phase 2 Not yet recruiting

134 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04617457 2024-01-12

HOLIPANC

Phase 2 Unknown

150 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT02539537 2024-01-09

NEOPAN

Phase 3 Completed

171 enrolled

Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT06166589 2023-12-12

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Phase 2 Not yet recruiting

19 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01897454 2023-12-05

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

Phase 2 Terminated

23 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00089024 2023-09-29

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Phase 2 Completed

29 enrolled 8 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04324307 2023-09-01

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

Phase 1/2 Unknown

60 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01726582 2023-08-14

Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")

Phase 2 Completed

229 enrolled 14 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT01835041 2023-07-12

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 1 Completed

21 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02620865 2023-05-15

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Phase 1/2 Completed

2 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

Clinical Trials

LAP100

PANGEA

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

PANCREAS

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

PANC

Pancreas

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

FOLFIRINOX + NIS793 in Pancreatic Cancer

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

PANThEON

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

PIOPPO

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

CENDIFOX

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

Nordic Pancreatic Cancer Trial (NorPACT) - 1

PREOPANC-3

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Peri-operative SLOG for Localized Pancreatic Cancer

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

HOLIPANC

NEOPAN

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer